Ann: Retina Target Engagement Confirmed in Large Eye, page-29

Both approaches makes sense to me.

Funding could well be finalised after tox results and larger animal testing confirmed as your broker mentions.
Question remains why to drive price down prior to such results during negotiation and meeting period with
investors and partners during the latest summits and conferences.

A meaningful contract takes time and initial goalposts at lower entry prices would be beneficial to partnering identity.
Internally such entry levels might be locked in and investor/ partner comes in at a premium to such.


I agree that the timing for the final contract to be shared with the market is a big question mark, the internal process though
to go through with such on the heels of achieved milestones and hurdles taken prior to the clinic
seems to be ongoing.

all IMO